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Aim 
To determine the most efficacious of three currently used drug regimens for the sedation of 
acutely agitated patients in the emergency department 
 
Methods 
We undertook a randomised, double-blind, triple-dummy, clinical trial in two metropolitan 
EDs (October 2014-August 2015). Patients, aged 18-65 years, requiring intravenous (IV) drug 
sedation for acute agitation were enrolled. Each was randomised to an IV bolus of either 
midazolam 5mg-droperidol 5mg, droperidol 10mg or olanzapine 10mg. Two top up doses 
were administered, if required: midazolam 5mg, droperidol 5mg or olanzapine 5mg, 
respectively. The primary outcome was time to adequate sedation.  
 
Results  
349 patients were enrolled. The baseline characteristics of the groups (age, gender, triage 
category, drug/alcohol intoxication) did not differ (p>0.05). However, the median (IQR) times 
to adequate sedation (minutes) differed significantly (p<0.001): midazolam-droperidol group 
5 (8), droperidol 11 (17), olanzapine 11 (20). Five minutes after the initial sedative 
administration, 55.9%, 24.3% and 29.2% of patients were adequately sedated, respectively, 
(p<0.001). At all other times, significantly more patients in the midazolam-droperidol group 
were adequately sedated (p<0.01).  Significantly fewer patients in the midazolam-droperidol 
group required top-up doses (28.0%, 59.5% and 60.8%, respectively, p<0.001) or rescue 
medication (1.7%, 13.5% and 25.8%, respectively, p<0.001). The proportion of patients in 
each group who experienced an adverse event did not differ (22.0%, 17.1% and 20.8%, 
respectively, p=0.63).   
 
Conclusion  
The midazolam-droperidol combination is the best drug regimen for sedation of the acutely 
agitated emergency department patient. These findings will inform best-practice guidelines 
for the management of this difficult patient group. 
 
